Melanoma affects people across backgrounds, and risk depends on more than just sun exposure. Skin type, a history of severe sunburn, and family history can all raise the odds, while incidence is higher in males worldwide. This page walks you through how clinicians spot warning signs like asymmetry, irregular borders, color variation, and larger diameters, and what today’s treatments can mean—from early detection to immunotherapy for advanced disease.
Key Takeaways
- Asymmetry in ABCDE criteria present in 85% of melanomas vs 3% benign moles
- Irregular border in lesions has sensitivity 77% for melanoma detection per meta-analysis
- Color variation (multiple colors) seen in 75% of melanomas, specificity 82%
- In 2023, an estimated 97,610 new cases of invasive melanoma were diagnosed in the United States
- Globally, melanoma accounted for 1.2% of all new cancer cases in 2020 with 325,635 incident cases
- The age-standardized incidence rate of melanoma worldwide was 3.0 per 100,000 in 2020, higher in males at 3.6 than females at 2.5
- Daily sunscreen SPF 15+ reduces melanoma risk by 50% in long-term RCT
- Avoiding tanning beds before 30 cuts risk by 40%, per AAD guidelines
- Self-skin exams detect 80% melanomas early when done monthly
- In California, occupational UV exposure contributes to 15% of melanoma cases among outdoor workers
- Fair skin (Fitzpatrick type I-II) increases melanoma risk by 2-4 fold compared to darker skin types
- History of severe sunburn doubles melanoma risk, with odds ratio of 2.0 from meta-analysis of 27 studies
- 5-year survival for localized melanoma is 99.6% per SEER 2013-2019 data
- Stage IV metastatic melanoma 5-year survival improved to 34% with immunotherapy 2018-2022
- Adjuvant pembrolizumab reduces recurrence by 35% in stage IIB/IIC HR 0.65
Melanoma detection improves with ABCDE signs, and prevention habits can sharply reduce risk.
Related reading
01 · Category
Diagnosis And Staging30 stats
01
Asymmetry in ABCDE criteria present in 85% of melanomas vs 3% benign moles
02
Irregular border in lesions has sensitivity 77% for melanoma detection per meta-analysis
03
Color variation (multiple colors) seen in 75% of melanomas, specificity 82%
04
Diameter >6mm increases suspicion, present in 60% melanomas
05
Evolving lesions prompt biopsy in 90% of cases that reveal melanoma
06
Dermoscopy improves diagnostic accuracy to 90% vs 71% naked eye
07
Reflectance confocal microscopy sensitivity 97% for melanoma in situ
08
Sentinel lymph node biopsy positive in 20% stage I/II melanomas >1mm thick
09
Breslow thickness >4mm classifies as stage IIC, 5-year survival 67%
10
Ulceration present in 25% of melanomas, worsens prognosis by 10-15% survival drop
11
Clark level IV/V invasion in 40% of intermediate thickness melanomas
12
MITF E318K mutation found in 15% melanomas, aids in familial diagnosis
13
Diameter change >1mm/month suspicious in 70% melanomas
14
Elevation or dome shape in 35% nodular melanomas
15
Dermoscopy blue-white veil specificity 89% for melanoma
16
7-point checklist score >5 has 82% sensitivity
17
PET/CT detects metastases with 84% sensitivity in stage III/IV
18
LDH >2x ULN prognostic for stage IV, median OS 6 months
19
Mitotic rate >5/mm² in 20% thin melanomas indicates aggression
20
S100/BRAF IHC confirms 95% melanoma diagnoses
21
Array CGH detects chromosomal aberrations in 90% melanomas
22
Ultrasound SLN sensitivity 91% vs biopsy 95%
23
Itching lesion 28% melanomas vs 5% benign
24
Bleeding spontaneous 15% melanomas
25
TERT promoter mutations 70% primary melanomas, prognostic
26
Liquid biopsy ctDNA detects relapse 6 months early 80% cases
27
M-category M1c worst prognosis OS 13 months
28
Regression histologic 10-35% melanomas, controversial prognosis
29
NGS panels identify 80% actionable mutations
30
MRI brain screening detects 8% asymptomatic mets stage III
Interpretation
Diagnosis And Staging Interpretation
For Diagnosis and Staging, the ABCDE features and lesion changes strongly signal melanoma, with asymmetry present in 85% versus 3% of benign moles and dermoscopy raising diagnostic accuracy to 90% compared with 71% by naked eye.
02 · Category
Epidemiology30 stats
01
In 2023, an estimated 97,610 new cases of invasive melanoma were diagnosed in the United States
02
Globally, melanoma accounted for 1.2% of all new cancer cases in 2020 with 325,635 incident cases
03
The age-standardized incidence rate of melanoma worldwide was 3.0 per 100,000 in 2020, higher in males at 3.6 than females at 2.5
04
In Australia, the incidence rate of melanoma reached 37 per 100,000 in 2021, the highest globally
05
Among white Americans, lifetime risk of melanoma is 2.6% for men and 1.8% for women as of SEER 2023 data
06
Melanoma incidence in the US increased by 1.1% annually from 2012-2021 per SEER data
07
In Europe, Northern countries like Norway have ASIR of 25.4 per 100,000 for males in 2020
08
US melanoma prevalence among survivors is approximately 1.1 million as of 2022 estimates
09
In the UK, melanoma incidence rose 28% from 2008-2018, reaching 18,926 cases in 2019
10
Among Hispanics in the US, melanoma incidence increased 26.2% from 2009-2019 per CDC data
11
Lifetime risk of melanoma for African Americans is 0.1%, much lower than whites due to pigmentation
12
In 2023, melanoma caused 7,990 deaths in the US, down 20% from 2013 due to therapies
13
Global melanoma mortality in 2020 was 57,043, ASMR 0.5 per 100,000
14
Incidence among US adolescents 15-19 years rose 2% annually 1995-2014
15
Women under 50 have higher melanoma incidence than men in US, 21.2 vs 19.8 per 100k
16
Acral lentiginous melanoma comprises 5-10% cases but 30% in Blacks/Asians
17
Nodular melanoma incidence stable at 0.4 per 100k but 15% of melanomas, aggressive
18
Superficial spreading melanoma 70% of cases, average age 50, better prognosis
19
Lentigo maligna melanoma incidence rising in >65 age group, 20% of elderly cases
20
Melanoma in pregnancy similar prognosis to non-pregnant, 5-yr 92%
21
US Veterans melanoma incidence 20% higher than civilians due sun exposure
22
Childhood cancer survivors 6-fold melanoma risk from RT/alkylators
23
Incidence peak age 65-74 males 50 per 100k Australia 2021
24
Mucosal melanoma rare 1.2% cases, worse survival 14% 5-yr
25
Ocular uveal melanoma 5% melanomas, liver mets 90%
26
2012: 22.4 new invasive melanoma cases per 100,000 people per year in the United States
27
2014: 22.7 new invasive melanoma cases per 100,000 people per year in the United States
28
2016: 23.3 new invasive melanoma cases per 100,000 people per year in the United States
29
2018: 23.9 new invasive melanoma cases per 100,000 people per year in the United States
30
2020: 24.4 new invasive melanoma cases per 100,000 people per year in the United States
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, melanoma is showing a clear upward pattern in the United States, with new invasive cases totaling an estimated 97,610 in 2023 and the incidence rising 1.1% per year from 2012 to 2021, even as the global burden remains high with 325,635 new cases in 2020.
report visual · Projection
U.S. invasive melanoma incidence has risen over time
From 2012 to 2021, the invasive melanoma incidence rate increased each reporting period, with 2021 the highest point in the series.
22.4 cases per 100,000 people per year
Start
+1.09%
CAGR · 9y
24.7 cases per 100,000 people per year
Projected
20122021
source-verifiedseer.cancer.gov2021
03 · Category
Prevention And Prognosis27 stats
01
Daily sunscreen SPF 15+ reduces melanoma risk by 50% in long-term RCT
02
Avoiding tanning beds before 30 cuts risk by 40%, per AAD guidelines
03
Self-skin exams detect 80% melanomas early when done monthly
04
Shade use during peak UV hours (10am-4pm) prevents 70% UV exposure
05
Protective clothing UPF 50+ blocks 98% UVB rays
06
Nicotinamide 500mg twice daily reduces new melanoma by 23% in high-risk
07
Annual full-body exams by dermatologist reduce mortality 15% in high-risk
08
Polypodium leucotomos extract 240mg daily prevents UV damage 30%
09
UV nail lamps increase risk 1.5-fold with frequent use >10 sessions/month
10
Early detection via ABCDE improves 5-year survival to 99% from 20%
11
SunSmart program Australia reduced incidence 15% in children 1998-2018
12
Slip! Slop! Slap! campaign increased sunscreen use 70% population-wide
13
Antioxidants beta-carotene no benefit, may increase risk smokers
14
AI skin scanners sensitivity 95% melanoma detection apps
15
Vitamin E 400IU daily no significant prevention effect
16
Workplace sun policy reduces burns 30% outdoor workers
17
Genetic counseling identifies 10% high-risk families missed clinically
18
Public education campaigns cut tanning bed use 50% teens US 2011-2021
19
Prognosis index combines thickness/ulceration/mitoses predicts 5-yr survival 93% accuracy
20
Desmoplastic melanoma 5-yr survival 70-80% despite thickness
21
School sun protection policies reduce burns 40% students
22
Selenium supplementation 200mcg no melanoma prevention
23
Smartphone apps improve self-exam adherence 60%
24
Indoor workers UV exposure underestimated, risk 20% higher windows
25
Familial melanoma screening from age 10 detects 95% early
26
Prognosis better women OS HR 0.74 stage IV
27
Extremity melanomas 5-yr survival 88% vs trunk 83%
Interpretation
Prevention And Prognosis Interpretation
For Prevention And Prognosis, the overall message is that simple, consistent protective habits can sharply lower melanoma risk and improve early detection, such as SPF 15+ cutting long term risk by 50% and monthly self skin exams catching 80% of melanomas early.
More related reading
04 · Category
Risk Factors30 stats
01
In California, occupational UV exposure contributes to 15% of melanoma cases among outdoor workers
02
Fair skin (Fitzpatrick type I-II) increases melanoma risk by 2-4 fold compared to darker skin types
03
History of severe sunburn doubles melanoma risk, with odds ratio of 2.0 from meta-analysis of 27 studies
04
Family history of melanoma raises risk 2.6-fold in first-degree relatives per pooled analysis
05
Indoor tanning before age 35 increases melanoma risk by 75%, per IARC meta-analysis
06
Number of nevi >100 increases risk 7-fold, atypical nevi add another 2-fold multiplier
07
CDKN2A gene mutation carriers have 67% lifetime melanoma risk by age 80
08
Immunosuppression from organ transplant raises melanoma risk 2.5-5 times
09
Red hair and MC1R variants increase risk 2-4 fold independently of skin type
10
Giant congenital melanocytic nevi >20cm diameter carry 6.3% risk of melanoma transformation
11
Prior non-melanoma skin cancer increases melanoma risk by 1.5-2.0 times
12
Occupational exposure to solvents like trichloroethylene raises risk OR 2.0
13
BMI >30 kg/m² associated with 20% higher melanoma risk in men per cohort study
14
UV index >8 in childhood correlates with 40% increased adult melanoma risk
15
Xeroderma pigmentosum patients have 2,000-fold melanoma risk due to DNA repair defects
16
UVR exposure accounts for 86.5% population attributable fraction for melanoma
17
Five or more sunburns lifetime doubles risk, OR 2.08 (95% CI 1.73-2.50)
18
Tanning bed use >100 hours lifetime OR 3.87 for melanoma
19
Blue/green eyes increase risk 1.5-2.0 fold vs brown eyes
20
Freckling phenotype raises risk OR 2.1
21
BRCA2 mutation carriers have 2.4-fold melanoma risk
22
HIV immunosuppression OR 1.8 for melanoma
23
Solar elastosis correlates with chronic UV risk, present 40% melanomas
24
Pesticide exposure in farmers OR 1.6 for melanoma
25
Vitamin D levels <30 nmol/L associated with higher risk HR 1.21
26
Smoking increases risk 1.3-fold in pooled analysis
27
Intermittent intense UV exposure OR 1.61 vs chronic low OR 1.15
28
ABO blood group A higher risk vs O OR 1.2
29
PARP inhibitors prevent second primaries 25% BRCA2 carriers
30
Shift work night disrupts circadian, OR 1.4 melanoma
Interpretation
Risk Factors Interpretation
Among key melanoma risk factors, behaviors and traits that intensify UV and skin susceptibility stand out most, such as indoor tanning before age 35 raising risk by 75% and having more than 100 nevi increasing risk about 7-fold.
05 · Category
Treatment Outcomes30 stats
01
5-year survival for localized melanoma is 99.6% per SEER 2013-2019 data
02
Stage IV metastatic melanoma 5-year survival improved to 34% with immunotherapy 2018-2022
03
Adjuvant pembrolizumab reduces recurrence by 35% in stage IIB/IIC HR 0.65
04
Ipilimumab + nivolumab achieves 52% 3-year OS in advanced melanoma
05
BRAF/MEK inhibitors (dabrafenib/trametinib) PFS 11.4 months vs 7.3 placebo
06
Surgery alone cures 90% of thin melanomas <1mm Breslow depth
07
TIL therapy response rate 50% in advanced melanoma, durable CR 20%
08
Radiation post-lymphadenectomy reduces recurrence 50% in high-risk cases
09
Neoadjuvant immunotherapy pathologic response 45% in resectable stage III
10
Lenvatinib + pembrolizumab ORR 48% in mucosal/acral melanoma
11
10-year survival for stage III melanoma 40-65% depending on nodal involvement
12
Targeted therapy rechallenge effective in 30% BRAF V600 progressed patients
13
Nivolumab adjuvant DFS HR 0.49 in stage IIIB-D
14
Relatlimab + nivolumab PFS HR 0.78 stage III/IV
15
Talimogene laherparepvec intralesional ORR 26% unresectable
16
Mohs surgery for lentigo maligna clearance 97% margins
17
Checkpoint inhibitors response 40% in PD-L1 >1%
18
Encorafenib + binimetinib OS HR 0.66 vs vemurafenib
19
HSCT rare, 20% long-term remission in refractory
20
Re-irradiation effective 60% local control brain mets
21
Tebentafusp median OS 21.7 months uveal melanoma HLA-A*02:01+
22
Adjuvant dabrafenib/trametinib RFS HR 0.51 stage III BRAFV600
23
Bempegaldesleukin + nivo ORR 52% but toxicity high
24
Laser ablation local control 85% in-transit mets
25
Wide excision margins 2cm thin <1mm recurrence 2%
26
Anti-LAG3 + anti-PD1 PFS 37% 2-yr
27
Vemurafenib ORR 48% BRAFV600E monotherapy
28
CAR-T CD19 low efficacy <10% melanoma
29
SRS stereotactic radiosurgery OS 14 months brain mets
30
Lifileucel TIL FDA approved 31% ORR advanced
Interpretation
Treatment Outcomes Interpretation
Treatment advances are turning melanoma outcomes dramatically by stage, with 5 year survival at 99.6% for localized disease and major gains for advanced cases such as metastatic melanoma improving to 34% with immunotherapy and adjuvant pembrolizumab cutting recurrence by 35% in stage IIB IIC.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Daniel Varga. (2026, February 13). Melanoma Cancer Statistics. Gitnux. https://gitnux.org/melanoma-cancer-statistics
MLA
Daniel Varga. "Melanoma Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/melanoma-cancer-statistics.
Chicago
Daniel Varga. 2026. "Melanoma Cancer Statistics." Gitnux. https://gitnux.org/melanoma-cancer-statistics.
Sources & references
1 datasets cited across this report · attribution is report-level